Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no study details appear to be changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedThe bottom notice about government funding and operating status was removed, with no changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check32 days agoChange DetectedNo significant changes detected between the two screenshots; only minor formatting adjustments to the study details page, and to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check61 days agoChange DetectedIntroducing a major update notice and current operating status guidance, along with a new version tag v3.2.0; the old version tag v3.1.0 has been removed.SummaryDifference3%

- Check68 days agoChange DetectedUpdate: version changed from v3.0.2 to v3.1.0; reflects a new release.SummaryDifference0.1%

- Check82 days agoChange DetectedPage version updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed.SummaryDifference0.2%

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.